Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
Loek A W de JongMarie LambertNielka P van ErpLukas de VriesEtienne ChatelutPetronella B OttevangerPublished in: Cancer chemotherapy and pharmacology (2023)
Systemic exposure to ultrafiltered cisplatin after intraperitoneal administration is high. In addition to a local effect, this provides a pharmacological explanation for high incidence of adverse events seen after intraperitoneal administration of high-dose cisplatin. The study was registered at ClinicalTrials.gov under registration number NCT02861872.